Relapsed/Refractory Multiple Myeloma: Future Directions in Treatment Sequencing and Patient Outcomes

Dr. Joshua Richter and Dr. Marco Davila conclude the discussion by reflecting on the future of relapsed/refractory multiple myeloma (RRMM) and the rapid evolution of cellular therapies and other novel treatment options. Dr. Davila identifies optimal treatment sequencing as one of the field's greatest remaining challenges, emphasizing the need to determine how best to integrate CAR T-cell therapy, bispecific antibodies, and other emerging therapies to maximize durable remissions and improve long-term patient outcomes. He highlights the remarkable progress achieved through ongoing translational and clinical research, noting that advances in therapy are shifting expectations toward the possibility of long-term disease control and, for some patients, potential cure. Dr. Richter reinforces the importance of collaboration between community oncologists and specialized treatment centers to ensure patients have timely access to advanced therapies and individualized care. The program concludes by emphasizing multidisciplinary collaboration, evidence-based treatment sequencing, and continued innovation as key priorities for improving outcomes in patients with RRMM.